ConductScience.org, home

Paper40484646

Targeting TBK1 potentiates oncolytic virotherapy via amplifying ICAM1-mediated NK cell immunity in chemo-resistant colorectal cancer.

Guo X and 13 others. J Immunother Cancer, 2025. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. Targeting TBK1 potentiates oncolytic virotherapy via amplifying ICAM1-mediated NK cell immunity in chemo-resistant colorectal cancer. Papers, record 40484646. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40484646

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Targeting TBK1 potentiates oncolytic virotherapy via amplifying ICAM1-mediated NK cell immunity in chemo-resistant colorectal cancer.
PubMed
Journal
J Immunother Cancer
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
1.61, provisional
iCite
Revised in PubMed
2025-06-14
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Guo XXin
2Feng HHuolun
3Xi ZZhihui
4Zhou JJi
5Huang ZZuda
6Guo JJieqing
7Zheng JJiabin
8Lyu ZZejian
9Liu YYongfeng
10Zhou JJianlong
11Zhang YYucheng
12Zhang YYuhan
13Li YYong
14Xing FFanhttps://orcid.org/0000-0001-7278-2513

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Colorectal NeoplasmsMajor topic
Oncolytic VirotherapyMajor topic
Killer Cells, NaturalMajor topic
Protein Serine-Threonine KinasesMajor topic
Intercellular Adhesion Molecule-1Major topic
Drug Resistance, NeoplasmMajor topic
Oncolytic VirusesMajor topic
Humans
Animals
Mice
Cell Line, Tumor
Female

Source PubMed

Download CSV of topics

References53

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136634707Targeting TBK1 to overcome resistance to cancer immunotherapy.Nature2023https://conductscience.org/library/papers/36634707PubMed
238750019Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways.Nat Commun2024https://conductscience.org/library/papers/38750019PubMed
327049944The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression.Nature2016https://conductscience.org/library/papers/27049944PubMed
436864254Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.Nat Med2023https://conductscience.org/library/papers/36864254PubMed
534747156An Inter-Supplementary Biohybrid System Based on Natural Killer Cells for the Combinational Immunotherapy and Virotherapy of Cancer.Adv Sci (Weinh)2022https://conductscience.org/library/papers/34747156PubMed
638167409Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma.Nat Commun2024https://conductscience.org/library/papers/38167409PubMed
738693119Fn-OMV potentiates ZBP1-mediated PANoptosis triggered by oncolytic HSV-1 to fuel antitumor immunity.Nat Commun2024https://conductscience.org/library/papers/38693119PubMed
837267951Methionine restriction promotes cGAS activation and chromatin untethering through demethylation to enhance antitumor immunity.Cancer Cell2023https://conductscience.org/library/papers/37267951PubMed
938519366Emerging roles of TBK1 in cancer immunobiology.Trends Cancer2024https://conductscience.org/library/papers/38519366PubMed
1017018283RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival.Cell2006https://conductscience.org/library/papers/17018283PubMed
1122781695Oncolytic virotherapy.Nat Biotechnol2012https://conductscience.org/library/papers/22781695PubMed
1230210920Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells.Am J Cancer Res2018https://conductscience.org/library/papers/30210920PubMed
1334117484Natural killer cells in antiviral immunity.Nat Rev Immunol2022https://conductscience.org/library/papers/34117484PubMed
1436385525Colon tumour cell death causes mTOR dependence by paracrine P2X4 stimulation.Nature2022https://conductscience.org/library/papers/36385525PubMed
1536765091Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy.Nat Commun2023https://conductscience.org/library/papers/36765091PubMed
1631792381TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression and tumourigenesis.Nat Cell Biol2019https://conductscience.org/library/papers/31792381PubMed
1738909621Colorectal cancer.Lancet2024https://conductscience.org/library/papers/38909621PubMed
1838211588Kinome-wide siRNA screen identifies a DCLK2-TBK1 oncogenic signaling axis in clear cell renal cell carcinoma.Mol Cell2024https://conductscience.org/library/papers/38211588PubMed
1937989995PTK2B promotes TBK1 and STING oligomerization and enhances the STING-TBK1 signaling.Nat Commun2023https://conductscience.org/library/papers/37989995PubMed
2035792620CDK4/6 Inhibition Enhances Oncolytic Virus Efficacy by Potentiating Tumor-Selective Cell Killing and T-cell Activation in Refractory Glioblastoma.Cancer Res2022https://conductscience.org/library/papers/35792620PubMed

See all 53 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42378815Mechanisms and advances of drug resistance in colorectal cancer: A systematic overview of multi-layered regulatory networks.Transl Oncol2026https://conductscience.org/library/papers/42378815PubMed
41923622Engineered oncolytic virus armed with anti-PCSK9 scFv boosts long-term CD8+ T cell immunity via rewiring MHC-I antigen presentation.Cell Rep Med2026https://conductscience.org/library/papers/41923622PubMed
41440025Oncolytic Virotherapy in Colorectal Cancer: Mechanistic Insights, Enhancer Strategies, and Translational Combinations.Cells2025https://conductscience.org/library/papers/41440025PubMed
41416429Advancements on the synergistic application of oncolytic viruses and molecularly targeted therapies for the treatment of solid tumors (Review).Int J Oncol2026https://conductscience.org/library/papers/41416429PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ICAM13383PubTator's text mininghttps://conductscience.org/library/genes/3383NCBI Gene
RIPK18737PubTator's text mininghttps://conductscience.org/library/genes/8737NCBI Gene
TBK129110PubTator's text mininghttps://conductscience.org/library/genes/29110NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40484646

GET https://conductscience.org/api/papers/v1/40484646/references?page=2